secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biomea Fusion, Inc. (BMEA)
CIK:        0001840439
Form:       8-K
Filed at:   2023-07-31T23:59:59+00:00
Accession:  0000950170-23-035939
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biomea Fusion Q2 2023: positive diabetes & AML data; net loss widens
--------------------------------------------------------------------

- Diabetes: in Cohort 3 (100 mg BMF-219 QD), mean HbA1c reduction of 1.49% at Week 12, 62% greater than at end of 4-week dosing.
- 60% of Cohort 3 patients achieved HbA1c ≤7% at Week 12 vs 30% at Week 4; no severe TEAEs off treatment.
- Oncology: 2 complete responses out of 5 relapsed/refractory AML patients carrying menin-dependent mutations at Dose Level 4.
- Cash $223.3M as of June 30, 2023; net loss $24.9M in Q2 2023 vs $17.3M in Q2 2022.
- Initiated Phase I for BMF-500 (COVALENT-103), a third-generation covalent FLT3 inhibitor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840439/000095017023035939/0000950170-23-035939-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840439/000095017023035939/bmea-20230731.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-035939

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer